Thibaut du Fayet, Pherecydes CEO
February 16, 2023 06:57 AM EST
Deals

Biotech con­sol­i­da­tion con­tin­ues as Nas­daq-list­ed Ery­tech merges with phage ther­a­py de­vel­op­er

Amber Tong

Just shy of two decades, the name of Ery­tech Phar­ma — and its mis­sion of us­ing red blood cells to de­liv­er drugs for rare can­cers and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times